Trials / Completed
CompletedNCT03387566
A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration
A Phase 1, Safety, Tolerability and Pharmacokinetic Profile Study of Intravitreous Injections of HB002.1M (a Vascular Endothelial Growth Factor Receptor Decoy) in Subjects With Neovascular Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Huabo Biopharm Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of HB002.1M, a human immunoglobulin Fc fusion protein containing domain 2 and flanking sequence of vascular endothelial growth factor (VEGF) receptor-1 in subjects with age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HB002.1M | HB002.1M is a Vascular Endothelial Growth Factor Receptor Decoy. |
Timeline
- Start date
- 2018-02-08
- Primary completion
- 2020-02-01
- Completion
- 2020-03-23
- First posted
- 2018-01-02
- Last updated
- 2020-07-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03387566. Inclusion in this directory is not an endorsement.